[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363709-105":59,"doc-detail-363709-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-elevated-c-reactive-protein-on-survival-outcomes-of-patients-with-small-renal-masses-a-retrospective-multicenter-analysis","Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis","","This study evaluates whether elevated pre-operative C-reactive protein (CRP) predicts survival outcomes in patients with small renal masses (SRM). Using a multi-institutional retrospective cohort of surgically managed SRM patients with tumor size ≤3 cm, participants were divided by CRP level (≥0.5 mg/dL vs \u003C0.5 mg/dL). Primary outcome was all-cause mortality, with secondary outcomes including non-cancer and cancer-specific mortality. Elevated CRP independently predicted higher risks of all-cause and non-cancer mortality, while cancer-specific mortality showed a smaller but significant association. Kaplan–Meier analyses demonstrated worse overall and non-cancer survival for non-elevated CRP. The findings support considering CRP-driven risk stratification and tailoring management toward appropriate surveillance or biopsy, particularly for indolent histology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-elevated-c-reactive-protein-on-survival-outcomes-of-patients-with-small-renal-masses-a-retrospective-multicenter-analysis/363709/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-elevated-c-reactive-protein-on-survival-outcomes-of-patients-with-small-renal-masses-a-retrospective-multicenter-analysis/363709.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To investigate how elevated pre-operative CRP impacts survival outcomes in patients with small renal masses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped in this analysis?",{"text":117,"@type":113},"Patients were classified into elevated CRP (≥0.5 mg/dL) versus non-elevated CRP (\u003C0.5 mg/dL) groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were assessed?",{"text":121,"@type":113},"The primary outcome was all-cause mortality, with secondary outcomes including non-cancer and cancer-specific mortality.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363709,1790822407,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nImpact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis  \nMargaret F. Meagher 1, Natalie Birouty 1, Giacomo Musso 1, Dattatraya Patil 2, Kazutaka Saito 3, Yosuke Yasuda 3, Dhruv Puri 1, Benjamin Baker 1, Kit Yuen 1, Jacob L. Roberts 1, Aaron Ahdoot 1, Omer Baker 1, Mai Dabbas 1, Julian Cortes 1, Yasuhisa Fujii 3, Viraj Master 2, Michael Liss 1 and Ithaar H. Derweesh 4, *  \nReceived: 23 March 2026  \nRevised: 28 May 2026  \nAccepted: 28 May 2026  \nPublished: 1 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Urology, University of California San Diego, San Diego, CA 92103, USA  \n2 Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA  \n3 Department of Urology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan  \n4 Department of Urology, Rush University Medical Center, Chicago, IL 60612, USA  \n* Correspondence: [iderweesh@gmail.com](iderweesh@gmail.com); Tel.: +1-(312)-563-3447; Fax: +1-(312)-563-3721  \nSimple Summary  \nThe optimal management of small renal masses (SRMs, \u003C4 cm) must balance the need for adequate cancer control with the risk of overtreatment. Current guidelines recommend consideration of serial imaging as an initial management strategy for patients with SRM, with surgical excision reserved for growing masses in young, healthy patients. However, even with increased de-emphasis on immediate surgery, overtreatment of benign and indolent renal cancer remains a quality-care concern. CRP is an inflammatory marker that is elevated in a variety of disease states such as cancer. We sought to investigate the prognostic value of pre-operative CRP in predicting survival outcomes in patients with small renal masses. We hope to provide additional information to guide patient counseling, with the goal of offering surveillance and surgery to appropriate patients while taking into account the competing risks of mortality.  \nAbstract  \nObjective: This study aimed to investigate the impact of elevated CRP on survival outcomes in small renal masses (SRM) . Methods: This was a multi-institutional retrospective analysis of SRM (≤3 cm) managed surgically. The cohort was divided into elevated CRP (≥0.5 mg/dL) vs. non-elevated CRP groups (\u003C0.5) . The primary outcome was all-cause mortality (ACM) . The secondary outcomes were non-cancer (NCM) and cancer-specific mortality (CSM) . Cox-regression analysis was used to elucidate predictive factors for mortality outcomes. Kaplan–Meier Analysis (KMA) was performed to analyze 10-year overall (OS), cancer-specific (CSS) and non-cancer-specific survival (NCS) . Results: A total of 1001 patients were analyzed (309 non-elevated CRP/692 elevated CRP; median follow-up 70 months). Elevated CRP was an independent predictor for ACM (HR = 2.60, p \u003C 0.001) NCM (HR = 2.90, p = 0.002), and CSM (HR = 1.20, p = 0.011) . KMA comparing elevated vs. non-elevated groups revealed greater 10-year OS (p \u003C 0.001) and NCS (p \u003C 0.001) for non-elevated CRP, but no significant difference in 10-year CSS (p = 0.295) . A total of 83 deaths were observed in elevated CRP (71 NCM/12 CSM—all clear-cell histology) . The sensitivity/specificity of elevated CRP was 0.87/0.33, 0.75/0.81, and 0.90/0.33 for ACM, CSM, and NCM. By utilizing CRP for a decision-making algorithm prioritizing biopsy in CRP elevation and offering surveillance in benign or indolent histology, surgery may be avoided in 218 patients, in whom there were 38 fatalities, all NCM. Conclusions: Elevated  \nCRP was an independent predictor of survival outcomes in SRM ≤ 3 cm. From a competing mortality standpoint, patients with elevated CRP had significantly worsened NCM compared to CSM. In such patients, upfront oncologic risk stratification through biopsy may be cons","cbCaiqQR8YjQ1Gjd","https://ap.wps.com/l/cbCaiqQR8YjQ1Gjd","pdf",754611,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n# 2. Patients and Methods\n## 2.1. Patient Population","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To investigate how elevated pre-operative CRP impacts survival outcomes in patients with small renal masses.\"},{\"question\":\"How were patients grouped in this analysis?\",\"answer\":\"Patients were classified into elevated CRP (≥0.5 mg/dL) versus non-elevated CRP (\\u003c0.5 mg/dL) groups.\"},{\"question\":\"What outcomes were assessed?\",\"answer\":\"The primary outcome was all-cause mortality, with secondary outcomes including non-cancer and cancer-specific mortality.\"}]","Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis | PDF",1790152765,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b305abc4026677f944c251de4a32355.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e2d0a88425006bc8a56b1c882d19103.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/147d10123485a5a7ca0b89c85a9a271d.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a76be95db276da51a8dea4d958a82518.webp",980,1385]